Skip to search formSkip to main contentSkip to account menu

anacetrapib

A cholesteryl ester transfer protein (CETP) inhibitor with hypocholesterolemic properties. Anacetrapib reduces the transfer of cholesteryl ester from… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
BACKGROUND Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin… 
Highly Cited
2015
Highly Cited
2015
The present study is the first intervention study in a well-established, translational mouse model for hyperlipidaemia and… 
Review
2014
Review
2014
Highly Cited
2011
Highly Cited
2011
In this report, we disclose our findings regarding the remarkable effect of a low-level impurity found in the solvent used for a… 
Highly Cited
2010
Highly Cited
2010
BACKGROUND Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol… 
Highly Cited
2010
Highly Cited
2010
Objective—To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on… 
Review
2010
Review
2010
Subnormal plasma levels of high-density lipoprotein cholesterol (HDL-C) constitute a major cardiovascular risk factor; raising… 
Highly Cited
2009
Highly Cited
2009
Systematic identification of protein-drug interaction networks is crucial to correlate complex modes of drug action to clinical… 
Highly Cited
2008
Highly Cited
2008
Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high density lipoprotein (HDL… 
Highly Cited
2008
Highly Cited
2008
Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the heteroexchange of cholesteryl esters from high…